Liminatus Pharma regains Nasdaq minimum bid price compliance after reverse stock split
LIMN•Liminatus Pharma said Nasdaq confirmed it met the $1.00 minimum bid price requirement after its 1-for-50 reverse stock split, based on 13 consecutive sessions above $1.00 from Aug. 21 to Sept. 9, 2026.
1. Compliance restored
Nasdaq confirmed Liminatus Pharma regained compliance with its $1.00 minimum bid price rule, closing a delisting risk tied to trading below that threshold. The company’s 1-for-50 reverse split took effect at the Aug. 20, 2026 close; the shares had been moved to the Nasdaq Capital Market effective Aug. 4, with a Sept. 3 compliance deadline.
